Petit T, Borel C, Rixe O, Avril M F, Monnier A, Giroux B, Weil M, Khayat D
Medical Oncology Unit, Salpetriere Hospital, Paris, France.
Cancer. 1996 Mar 1;77(5):900-2.
In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma.
One hundred sixty-nine patients with metastatic malignant melanoma were included in this Phase II study. One hundred fifty-three patient records were evaluable with an overall response rate of 24.2%.
Five of these patients are alive and in complete remission. One patient had a complete response after fotemustine administration and then relapsed. One patient had a partial response. Three patients had stable disease. These five patients underwent surgery for relapse or residual disease and subsequently achieved durable complete remission.
Long term survival may be the outcome after surgical resection of residual metastatic melanoma after chemotherapy.
在本研究中，作者确定了在法国多中心福莫司汀治疗转移性恶性黑色素瘤II期试验完成后的七年幸存者。
169例转移性恶性黑色素瘤患者纳入本II期研究。153例患者记录可评估，总缓解率为24.2%。
这些患者中有5例存活且完全缓解。1例患者在给予福莫司汀后完全缓解，随后复发。1例患者部分缓解。3例患者病情稳定。这5例患者因复发或残留病灶接受了手术，随后实现了持久的完全缓解。
化疗后手术切除残留转移性黑色素瘤可能带来长期生存的结果。
